Xvivo Perfusion AB (XVIPF) Income Statement
Xvivo Perfusion AB Income Statement
Last quarter (Q3 2026), Xvivo Perfusion AB's total revenue was $252.56M, an increase of 33.53% from the same quarter last year. In Q3, Xvivo Perfusion AB's net income was $44.62M. See Xvivo Perfusion AB’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 812.16M | $ 822.41M | $ 597.54M | $ 415.29M | $ 258.39M | |
| $ 533.50M | $ 616.41M | $ 445.11M | $ 296.96M | $ 188.28M | |
| $ 440.48M | $ 528.06M | $ 440.92M | $ 292.50M | $ 207.02M | |
| Depreciation and Amortization | $ 70.21M | $ 67.42M | $ 30.86M | $ 42.17M | $ 32.26M |
| $ 153.14M | $ 272.97M | $ 35.05M | $ 65.58M | $ 39.20M | |
| $ 93.02M | $ 88.35M | $ 4.19M | $ 23.18M | $ 6.98M | |
| $ -54.46M | $ 111.59M | $ 90.33M | $ -867.00K | $ -317.00K | |
| $ 38.56M | $ 199.95M | $ 94.52M | $ 22.31M | $ 6.67M | |
| $ 25.16M | $ 172.18M | $ 91.82M | $ 18.43M | $ 8.15M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.80 | $ 5.47 | $ 3.07 | $ 0.62 | $ 0.28 |
| Diluted EPS | $ 0.80 | $ 5.44 | $ 3.07 | $ 0.62 | $ 0.28 |
| Weighted Average Shares Outstanding | 31.50M | 31.50M | 29.94M | 29.53M | 28.85M |
| Weighted Average Shares Outstanding (Diluted) | 31.56M | 31.67M | 29.94M | 29.53M | 28.94M |
Currency in SEK
